So pleased to have had an opportunity to catch-up with editorial board member, K Ray Chaudhuri (King’s Parkinson’s Centre, King’s College Hospital and Kings College London, UK), who shared his expert perspective on the clinical impact of COVID-19 on people with Parkinson’s disease.
Questions
1. What treatment strategies should be implemented in patients with Parkinson’s disease (PD) and pneumonia or upper respiratory tract infections resulting from COVID-19? (0:05)
2. What potential drug–drug interactions may occur between PD medications and drugs used to treat symptoms of COVID-19? (2:06)
3. What are the consequences of anxiety and prolonged immobility due to the lockdown on patients with PD? (2:49)
4. What other advice would you like to impart to healthcare professionals regarding patient management at this time? (4:39)
Also see linked video: K Ray Chaudhuri, EAN 2020 – Clinical Impact of COVID-19 on People With Parkinson’s Disease
Speaker disclosure: K Ray Chaudhuri has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media.
Filmed at the 6th Congress of the European Academy of Neurology (EAN) and 1st EAN Virtual Congress, May 2020.
